Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309039723> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W4309039723 abstract "Abstract: The SARS-CoV-2 pandemic has significantly impacted world health and economic status. In response, much work has been undertaken to provide effective, safe vaccines, antibodies and antiviral drugs with which to address this pandemic. Treatment of a pandemic population presents multiple challenges in addition to the primary issue of drug efficacy and safety, such as large scale drug manufacture and distribution, drug stability, oral dosing and pharmacoeconomic considerations. Ideally, these factors must be addressed if new candidate drugs are to be advanced for treatment of large (pandemic) populations. Subsequently, new antivirals have reached the market but choices are few. According to the NIH Covid Treatment Guidelines, only three small molecule antiviral drugs are available to treat COVID-19 disease. As such, a significant part of the research towards discovery of new antiviral drugs has focused on screening and evaluation of ‘repurposed drugs’ or previously approved or clinical stage drugs. Yet, in spite of this increased research activity, one promising clinical stage candidate drug has received little attention regarding its potential as a monotherapy or component of combination therapy for treatment of COVID-19 disease. Tucaresol, with documented human safety and pharmacokinetic data, is an orally active, stable, small molecule amenable to large scale manufacture by a proprietary two-step synthesis developed by us. Tucaresol functions as a host-targeted antiviral by selective protection/reconstitution of CD4+ T helper cells as demonstrated in HIV patients and SIV macaques. In view of similarities between HIV and SARS-CoV-2, especially with respect to host CD4+ T helper cells, and the suitability of Tucaresol for facile treatment of pandemic populations, Tucaresol is presented herein for treatment of mild-to-moderate COVID-19 patients but may also be useful for treatment of advanced disease accompanied by lymphopenia." @default.
- W4309039723 created "2022-11-21" @default.
- W4309039723 creator A5002337843 @default.
- W4309039723 creator A5019413639 @default.
- W4309039723 creator A5058305239 @default.
- W4309039723 date "2022-11-11" @default.
- W4309039723 modified "2023-09-26" @default.
- W4309039723 title "Tucaresol: A Unique Oral Candidate Drug Ideally Accessible for Treatment of COVID-19 Disease" @default.
- W4309039723 doi "https://doi.org/10.20944/preprints202211.0221.v1" @default.
- W4309039723 hasPublicationYear "2022" @default.
- W4309039723 type Work @default.
- W4309039723 citedByCount "0" @default.
- W4309039723 crossrefType "posted-content" @default.
- W4309039723 hasAuthorship W4309039723A5002337843 @default.
- W4309039723 hasAuthorship W4309039723A5019413639 @default.
- W4309039723 hasAuthorship W4309039723A5058305239 @default.
- W4309039723 hasBestOaLocation W43090397231 @default.
- W4309039723 hasConcept C126322002 @default.
- W4309039723 hasConcept C177713679 @default.
- W4309039723 hasConcept C2777288759 @default.
- W4309039723 hasConcept C2777494893 @default.
- W4309039723 hasConcept C2779134260 @default.
- W4309039723 hasConcept C2779756493 @default.
- W4309039723 hasConcept C2780035454 @default.
- W4309039723 hasConcept C2908647359 @default.
- W4309039723 hasConcept C3008058167 @default.
- W4309039723 hasConcept C524204448 @default.
- W4309039723 hasConcept C71924100 @default.
- W4309039723 hasConcept C89623803 @default.
- W4309039723 hasConcept C98274493 @default.
- W4309039723 hasConcept C99454951 @default.
- W4309039723 hasConceptScore W4309039723C126322002 @default.
- W4309039723 hasConceptScore W4309039723C177713679 @default.
- W4309039723 hasConceptScore W4309039723C2777288759 @default.
- W4309039723 hasConceptScore W4309039723C2777494893 @default.
- W4309039723 hasConceptScore W4309039723C2779134260 @default.
- W4309039723 hasConceptScore W4309039723C2779756493 @default.
- W4309039723 hasConceptScore W4309039723C2780035454 @default.
- W4309039723 hasConceptScore W4309039723C2908647359 @default.
- W4309039723 hasConceptScore W4309039723C3008058167 @default.
- W4309039723 hasConceptScore W4309039723C524204448 @default.
- W4309039723 hasConceptScore W4309039723C71924100 @default.
- W4309039723 hasConceptScore W4309039723C89623803 @default.
- W4309039723 hasConceptScore W4309039723C98274493 @default.
- W4309039723 hasConceptScore W4309039723C99454951 @default.
- W4309039723 hasLocation W43090397231 @default.
- W4309039723 hasOpenAccess W4309039723 @default.
- W4309039723 hasPrimaryLocation W43090397231 @default.
- W4309039723 hasRelatedWork W100428987 @default.
- W4309039723 hasRelatedWork W1517854031 @default.
- W4309039723 hasRelatedWork W2086036313 @default.
- W4309039723 hasRelatedWork W2124466768 @default.
- W4309039723 hasRelatedWork W2912785940 @default.
- W4309039723 hasRelatedWork W2943083791 @default.
- W4309039723 hasRelatedWork W3011998294 @default.
- W4309039723 hasRelatedWork W3023724901 @default.
- W4309039723 hasRelatedWork W3086943032 @default.
- W4309039723 hasRelatedWork W77253860 @default.
- W4309039723 isParatext "false" @default.
- W4309039723 isRetracted "false" @default.
- W4309039723 workType "article" @default.